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Summary
Background: New oral anticoagulants (NOACs) are 
predicted to become the new standard treatment for 
stroke prevention in patients with atrial fibrillation, 
and may replace vitamin K antagonists (VKAs). 
 NOACs are prescribed less than expected, even though 
they do not require international normalised ratio 
(INR) monitoring. In this study we assessed methods 
for INR monitoring after the introduction of NOACs a 
in heterogeneous sample of countries.
Methods: We asked representatives of the Vasco da 
Gama Movement, a network of junior and future gen-
eral practitioners (GPs) in Europe, and WONCA, the 
World Organization of Family Doctors, to describe the 
way INR is monitored in their respective countries. 
Results: Representatives of 14 countries responded. 
In most countries, the INR is monitored by GPs; in 
some countries, these patients are treated by other 
 specialists or in specialised anticoagulation centres. In 
only a few countries, anticoagulated patients monitor 
the INR themselves. 
Conclusion: Our study showed several strategies 
for managing anticoagulation in different countries. In 
most countries, the INR is monitored by GPs. These 
consultations offer opportunities to address other is-
sues, such as blood pressure control or medication 
 adherence. These factors may be considered when de-
ciding to switch patients from VKAs to NOACs. 
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Introduction
New oral anticoagulants (NOACs) have become avail-
able in recent years, with the main advantage of a fixed 
oral dosage, so that the regular assessment of interna-
tional normalised ratio (INR) val-
ues and subsequent dosage adjust-
ment of vitamin K antagonists 
(VKAs) by a professional was no 
longer required. Owing to their ef-
ficacy and noninferiority to VKAs, 
NOACs “appear to hit the sweet spot of both improved 
efficacy and safety” [1] and they were expected to be-
come the new standard treatment for stroke preven-
tion in patients with atrial fibrillation (AF). 
However, even though NOACs have been available 
for some time, opinion remains divided about imple-
menting them. In recent studies several reasons that 
may explain a lack of implementation were mentioned. 
First, patients or general practitioners (GPs) may not 
want to switch, because they are familiar and comfort-
able with VKAs when INR values are consistently in 
therapeutic range [1], or because they are comfortable 
with managing perioperative adjustments in VKA 
 dosing [2]. Second, studies have not shown an increase 
in the quality of life for patients using NOACs com-
pared to VKA (measured as quality-adjusted life years) 
[3]. Third, in patients with good or excellent control, 
switching to NOACs may cause additional risk of ma-
jor gastrointestinal bleeding or other adverse  effects 
[4]. There are well-validated strategies for the manage-
ment of bleeding complications, should they occur, 
when using a VKA [5], but these are currently not 
available for NOACs. 
Another issue complicating matters is that current 
practice of VKA treatment is different all over the 
world. To gain insight into current anticoagulation 
practice and the rationale behind choice of therapy, we 
undertook this survey to provide an overview of anti-
coagulant therapy from diverse countries after the 
 introduction of NOACs.
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Methods
We assessed the way INR is monitored in a cross- 
sectional study by using a questionnaire. The question-
naire was sent to all members of the Vasco da Gama 
Movement (VdGM), a network of junior and future 
GPs, which includes at least one member from most 
countries in Europe. We also sent the questionnaire to 
family doctors identified through the World Organiza-
tion of Family Doctors (WONCA), in order to reach 
more remote countries. Since the participants in the 
survey were GPs or trainees involved in international 
collaboration, the validity of their knowledge of their 
countries’ systems was relatively high.
The questionnaire was sent at the beginning of 
 October 2012 and consisted of a case of an 80-year-old 
man with AF who needs anticoagulation treatment 
 because of his CHADS2 score, without any contraindi-
cations. Respondents were asked to describe how this 
patient would be treated in their country and who 
would do the follow-up.
Results
The questionnaire was sent to 40 different countries of 
which 14 responded (response rate 35%) (fig. 1). In  table 
1 we provide an overview of the description of anti-
coagulation therapy in these countries. If monitoring 
was performed in different settings in a country (e.g., by 
GPs and anticoagulation centres), it was counted once 
for each measure. INR monitoring is performed by GPs 
in ten (71%) countries, by other specialists in six (43%), 
by specialised anticoagulation centres in five (36%) 
countries, and by the patients themselves in three (21%) 
countries (fig. 2). Totals add up to more than 100% be-
cause some countries had more than one mode of moni-
toring.
Respondents stated that an advantage of prescrib-
ing VKAs was that consultations for managing anti-co-
agulation also offered opportunities to address other 
conditions for patients with multimorbidity, which is es-
pecially prominent in these patients. While some 
 respondents mentioned higher costs as limiting the use 
of NOACs, others believed that seeing patients on a 
 regular base is necessary to prevent loss of quality of 
care (appendix A).
Discussion
Summary of the main findings
This study provided an overview of current anticoagula-
tion therapy management in general practice from 14 
different countries. In most countries, the INR is still 
monitored by GPs, in some countries it is monitored by 
specialists or at specialised centres and in only a few 
countries do patients self-manage their VKA  dosage. 
Some respondents were critical of the use of NOACs, 
since many patients requiring anticoagulation therapy 
suffer from several other diseases, which can also be ad-
dressed during anticoagulation consultations. 
Strengths and limitations
The main strength of our study is that we provide an 
overview from a heterogeneous sample of countries from 
all over the world. One limitation of our study is that the 
sample is small and the response rate of 35% was low. 
However, it does demonstrate the variety of strategies 
for managing and monitoring anti-coagulation all over 
the world. Another limitation is that one person de-
scribed the situation for a country. Since the respond-
ents are active members of their national organisations 
and participate actively in international activities, they 
have relatively high knowledge of their health care sys-
tems and this should not have influenced results.
Interpretation in relation to current literature
The uncertainty surrounding the choice of anticoagu-
lants is reflected in recommendations in international 
guidelines [6]. The American College of Cardiology 
Figure 1
Overview of replying countries: Chile, China, Finland, Greece, Israel, Italy, Nepal, 
Netherlands, Norway, Panama, Slovenia, Switzerland, Turkey, United States of 
America.
Figure 2
Different methods for monitoring INR in different countries. The x-axis represents 
the number of mentions of each method per questionnaire. Multiple answers were 
possible.
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Table 1
Different methods of measuring and monitoring international normalised ratio (INR) in 14 countries around the world.
Country INR monitoring
Chile 
 
Both in private clinics and in public hospitals there are policlinics for anticoagulation where a patient's  
INR is monitored. These clinics are run by internists who see patients and evaluate the dosage. In rural areas,  
this is carried out by GPs.
China  
(Hong Kong  
and Mainland) 
 
 
In both Mainland China and Hong Kong, most warfarin is prescribed and monitored by internists at hospital clinics. 
For most cases, the attending physician arranges for the INR to be checked in the laboratory before  
every follow up visit. In Hong Kong, INR monitoring is also provided by family physicians at family medicine specialist 
clinics or at community health clinics. In Mainland China, general practitioners in community health centres also help 
in monitoring warfarin treatment. The use of new oral anticoagulants is limited, which is mainly related to their high 
cost. 
Finland 
 
 
 
 
 
 
Most of the patients get their INR monitored in health centres by their GP or a nurse. Most commonly,  
the patient visits a laboratory and after that calls the healthcare centre and is informed of the new dosage. Recently 
there are new ways. Some of the patients are trained to perform self-monitoring and they receive  
their INR values directly from laboratory as a text message to their mobile phones. Sometimes nurses evaluate the 
dosage and send that to the patient via eLetter by normal mail or via the Web where patients have a link  
to their e-mail and get the dosage in a special Web portal at same time that it is sent. Of course if the INR value is 
very high or low the nurse will call them and make sure that they receive the new dosage. Elderly people can have 
their INR monitored at home by their home-care nurses.
Greece 
 
 
GPs do not start the initial therapy with anticoagulants in AF but they can monitor the INR if they want  
and know how to. The patient goes to the hospital or to a private microbiologist and has a blood check every  
4 to 6 weeks if stable. Then he presents the results to either the cardiologist, internal medicine doctor or GP, 
depending on who is most accessible.
Israel 
 
 
INR monitoring is done by GPs. The patients have regular blood checks in their clinic (usually the neighbourhood 
clinic), taken by a nurse. The result is emailed to their personal GP, and they can see it on the Web too. Usually the GP 
calls them and lets them know about the change needed in the warfarin dose. There are some clinics with on-the-
spot INR machines, and again the GP gets the result and tells the patient what to do.
Italy 
 
 
 
 
In urban centres, a GP who first evaluates such a patient refers him to the nearest centre for oral anticoagulant 
therapy: these centres consists of a laboratory, a cardiologist and a nurse. These centres measure the INR and initiate 
therapy. They follow up the patients and adjust the dosage accordingly (this is usually done by the cardiologist). Each 
patient informs the centre of changes in their medication so that they adjust the frequency  
of the INR measurements and the dosage adjustment. In rural areas where these centres don't exist, GPs manage the 
dosing by themselves. The INR measurement is usually carried out in laboratories in the nearby health centres.
Nepal Patients are sent to a laboratory. With the report they go to their GP or internist for dosage monitoring.
Netherlands 
 
There is a special organisation that measures the INR and provides patients with the dosage for their vitamin K 
antagonist. They work entirely independent of GPs and hospitals. Even when the INR is much too high they themsel-
ves will give vitamin K. 
Norway 
 
 
 
 
 
Most patients get their INR measured at their general practice every 4 to 6 weeks if stable, and more often if 
unstable. The GPs manage this quite differently. Almost every patient gets blood drawn by a health secretary / nurse 
at the clinic, or a nurse brings a blood sample to the clinic if the patient is house-bound / not mobile.  
Then some GPs have “normal” length consultations (15/20 minutes) for every INR control, other have short consulta-
tions in their calendar (5/10 minutes), and others again just tell their patients to drop by, and they  
call them in after the INR is ready, between other patients. Some young and quite healthy patients do their  
own testing and dosage adjustments.
Panama 
 
 
 
It is more complex in the public health system. INR is measured only in a blood sample taken from the arm,  
not capillary, and the result is usually not the same day. GPs may see the patient and change the dose, though often 
patients are sent to an anticoagulation clinic with internists, where the laboratory test result is the same day. 
However, this clinic is only in Panama City in the tertiaryl hospital. In the private sector INR results are available the 
same day, and mostly adjusted by internists.
Slovenia 
 
 
 
Usually internal medicine specialists monitor INR at hospitals and at some bigger primary health centres. Specially 
trained GPs run this service in smaller primary health centres and in primary-care private settings.  
There is a trend, that INR monitoring should be more widely performed at the primary-care level.  
Self-monitoring is unusual in Slovenia. Also NOACs are rarely used, due to high prices and prescription  
restrictions which are set by Slovenia’s national health insurance company.
Switzerland Most patients are monitored by their GP with a point-of-care device so the INR result is instantly available.  
Some patients are trained to perform self-monitoring.
Turkey The patients regularly go to an internal medicine specialist who monitors and changes the dosage.
United States 
 
Mostly family doctors have the blood drawn at their practice, but send the specimen to a reference or hospital 
laboratory, and then call the patient later with the results and advice on management of the anticoagulation. Some 
health systems have a pharmacist call the patient instead. 
AF = atrial fibrillation; GP = general practitioner; NOAC = new oral anticoagulant
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Foundation / American Heart Association Task Force on 
Practice Guidelines note “Because of ... the greater risk 
of non-hemorrhagic side effects ... patients already tak-
ing warfarin with excellent INR control may have little 
to gain by switching ...”. On the other hand, a  systematic 
review including >50,000 patients on NOACs showed a 
significant reduction in major and intra cranial bleeding 
compared with VKAs [7].
Studies suggest that the accessibility of primary-
care practice may affect the efficiency and effectiveness 
of oral anticoagulation management. Proposed strate-
gies to improve monitoring access in primary care 
 include careful follow-up of patient adherence and 
missed appointments [8], same-day availability of labo-
ratory results, comprehensive patient education [9], 
training of other healthcare personnel to oversee moni-
toring, and various self-care models [10]. Thus, the use 
of VKAs may still improve, which would further dimin-
ish the advantages of anticoagulation drugs such as 
NOACs that do not require monitoring.
Implications for clinical practice
The management of multimorbidity is a key issue for 
GPs. The use of VKAs gives patients the opportunity to 
have regular contact with their GP’s practice, and regu-
lar measurement of INR levels provides insights on pa-
tient comprehension and compliance. After switching to 
NOACs, valuable knowledge about adherence may be 
lost. Therefore, we speculate that switching to  NOACs 
not only affects stroke prevention, bleeding  rates, the in-
convenience of INR monitoring and costs, but also has 
an impact on the quality of care of patients with multi-
morbidity.
Conclusion
Using a global network of GPs, we provided insight into 
current anticoagulation therapy in 14 countries in dif-
ferent parts of the world. In summary, although several 
strategies for monitoring INR are being used in daily 
practice, in most countries primary-care physicians pro-
vide INR monitoring. Respondent GPs also raised criti-
cal issues about the loss of opportunities to provide ad-
ditional care to their patients when they visit for INR 
monitoring, which is especially important since multi-
morbidity is often prevalent in patients on anti-
coagulants. This additional factor may be considered 
when deciding whether to switch from VKA to NOAC 
anti-coagulation. 
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Appendix A
Remark by a responding general practitioner on moni-
toring INR:
“About 10 years ago, we went to a point of care  approach 
– the patient has an INR done by fingerstick at our prac-
tice and then sits down with our head nurse right after 
to discuss whether to continue or modify their current 
dose. The key difference is that it is our practice nurse 
(not someone calling from the hospital) who knows the 
patient, understands the importance of keeping the fam-
ily doctor informed, and sits down to discuss INR results 
with the patient. One example I give is that my nurse 
told the patient to return the next day because she was 
concerned about possible depression, and I diagnosed 
him the next day as suicidal due to  major depressive dis-
order. She likely saved his life by knowing him, and by 
getting him connected to me.”
